Featured image: A laboratory microscope illustrates cancer-biotechnology research. Contextual photograph; not PSV359, a patient image or a trial site. Photo: Ousa Chea / Unsplash. Unsplash licence.
A rare-cancer programme has gained a faster route for conversations with the US regulator. That is useful, but it is not the same thing as permission to sell a medicine.
On 8 October 2026, Perspective Therapeutics said the US Food and Drug Administration had granted Fast Track designation to PSV359 for adults with locally advanced unresectable or metastatic FAP-positive solitary fibrous tumours. The radiopharmaceutical is still investigational and is being studied in a recruiting Phase I/IIa trial. Read the company’s announcement.
The target sits around and sometimes on the tumour
FAP is fibroblast activation protein. It can be found on cancer-associated fibroblasts, cells in the supporting tissue around a tumour, and on some cancer cells. A FAP-targeting molecule is intended to carry its radioactive payload to that environment rather than distributing it without a guide.
PSV359 uses lead-212, written 212Pb, which produces alpha-particle radiation through its decay chain. Alpha particles travel only a short distance in tissue but deposit substantial energy. The approach therefore combines molecular targeting with local radiation; neither feature guarantees that enough drug reaches every tumour or that nearby normal tissue is spared. The developer’s description of the mechanism.
The programme also uses imaging before treatment. Lead-203 PSV359 or gallium-68 PSV377 is intended to show whether a person’s tumours take up the target-binding compound. This theranostic model links a diagnostic scan with a related therapy, although a visible imaging signal does not by itself establish clinical benefit.
Fast Track changes the regulatory process, not the evidence
The FDA explains that Fast Track is intended for drugs addressing serious conditions and an unmet medical need. It can bring more frequent meetings and written communication, and may allow a company to submit completed sections of an application on a rolling basis. Eligibility for other expedited programmes can follow if their separate standards are met. FDA explanation of Fast Track.
The designation does not mean the FDA has found PSV359 safe or effective, and it is not an approval. No marketing application has been approved through this announcement. The distinction matters because regulatory vocabulary can otherwise make an early programme sound like a finished treatment.
Fast Track is best understood as a way to reduce avoidable delay while evidence is generated and reviewed. The evidence requirements remain: a developer still has to characterise manufacturing, dose, safety and clinical activity.
The trial is designed to find a dose
The registered study, NCT06710756, is an open-label Phase I/IIa trial in advanced FAP-positive solid tumours. Its dose-escalation stage primarily examines safety, tolerability and a recommended dose. The expansion stage adds antitumour activity as a primary objective. The registry estimates 112 participants and completion in 2032; both the size and schedule can change. See the registered trial.
Open-label means participants and investigators know which treatment is being given. Dose escalation exposes small groups to increasing amounts under defined rules. This design is suited to learning how a new radiopharmaceutical behaves, but it does not offer the comparative evidence of a randomised late-stage trial.
Solitary fibrous tumours are rare, and the Fast Track indication is narrower than the trial’s broader solid-tumour population. Results will need to identify the tumour type, dose, imaging criteria and number of treated participants rather than pooling every patient into one claim.
The next useful result is measured, not implied
The programme will become more interpretable when investigators report dose-limiting toxicities, organ radiation exposure, tumour uptake, responses and their duration. A scan can help select patients, but the treatment still has to show that its radiation reaches disease in a clinically useful way.
For now, the meaningful development is procedural: a rare-cancer programme can work more closely with the FDA while an early trial proceeds. Fast Track may accelerate review. It cannot substitute for the trial results that would justify an approval.
Leave a Reply